American Society of Clinical Oncology

SHERPA: White

People

  1. Pfister
    Pfister
  2. Sherman
    Sherman
  3. Dunn
    Dunn
  4. Ho
    Ho
  5. Lee
    Lee
  6. Eng
    Eng
  7. McBride
    McBride
  8. Riaz
    Riaz
  9. Zhi
    Zhi
  10. Aghalar
    Aghalar

Groups

  1. Department of Medicine (10)
  2. Head and Neck Service (10)
  3. Solid Tumor Oncology Division (10)
  4. Thoracic Oncology (10)
  5. Biostatistics Service (5)
  6. Epidemiology and Biostatistics (5)
  7. Neuroradiology Service (5)
  8. Radiation Oncology, Department of (5)
  9. Radiology, Department of (5)
  10. Survivorship Research (5)
Search Within
  1. "David Pfister"
  2. "Thoracic Oncology"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (3)
Groups
  1. Department of Medicine (10)
  2. Head and Neck Service (10)
  3. Solid Tumor Oncology Division (10)
  4. Thoracic Oncology (10)
  5. Biostatistics Service (5)
  6. Epidemiology and Biostatistics (5)

More Groups

People
  1. David Pfister (10)
  2. Eric Sherman (7)
  3. Alan Ho (5)
  4. Lara Dunn (5)
  5. Loren Michel (5)
  6. Nancy Lee (5)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (1)
  5. 2019 (1)
  6. 2018 (1)

More Years

Publications
  1. Journal of Clinical Oncology (10)

Results (10)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Hypoxia-directed treatment of human papillomavirus-related oropharyngeal carcinoma
    Journal Article

    Lee, N. Y.; Sherman, E. J.; Schòˆder, H.; Wray, R.; Boyle, J. O.; Singh, B.; Grkovski, M.; Paudyal, R.; Cunningham, L.; Zhang, Z.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Assessing effectiveness of first-line carboplatin, pemetrexed, and pembrolizumab in patients with recurrent/metastatic lung adenocarcinoma
    Meeting Abstract

    Ip, A.; Gutierrez, M.; Warren, M. E.; Pfister, D. G.; Brady, O.; Shen, R. L.; Riely, G. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma
    Journal Article

    McBride, S.; Sherman, E.; Tsai, C. J.; Baxi, S.; Aghalar, J.; Eng, J.; Zhi, W. I.; McFarland, D.; Michel, L. S.; Young, R.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Dunn, L.; Ho, A. L.; Eng, J.; Michel, L. S.; Fetten, J. V.; Warner, E.; Kriplani, A.; Zhi, W. I.; Ng, K. K.; Haque, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    McBride, S. M.; Lee, N. Y.; Pfister, D. G.; Sherman, E. J.; Tsai, C. J.; Aghalar, J.; Eng, J.; Zhi, W. I.; McFarland, D. C.; Michel, L. S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    McBride, S. M.; Sherman, E. J.; Tsai, C. J.; Baxi, S. S.; Aghalar, J.; Eng, J.; Zhi, W. I.; McFarland, D. C.; Michel, L. S.; Spielsinger, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase I study of weekly albumin-bound paclitaxel (ab-P) plus weekly cetuximab (Cet) plus intensity-modulated radiation therapy (IMRT) in patients with stage III/IVb head and neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Fury, M. G.; Sherman, E. J.; Rao, S. S.; Wolden, S. L.; Smith-Marrone, S.; Ng, K. K.; Mueller, B.; Gelblum, D. Y.; Dutta, P. R.; Lee, J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m(2) for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Meeting Abstract

    Fury, M. G.; Sherman, E. J.; Lisa, D. M.; Agarwal, N.; Algazy, K. M.; Brockstein, B.; Langer, C. J.; Lim, D.; Mehra, R.; Rajan, S. K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase I dose escalation trial of pulsatile high dose gefitinib and docetaxel in patients with an advanced solid tumor
    Meeting Abstract

    Fury, M. G.; Kris, M.; Solit, D.; Pfister, D. G.; Azzoli, C. G.; Henry, R.; Su, Y. B.; Rizvi, N.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Initial clinical trial of a selective retinoid X receptor ligand, LGD1069
    Journal Article

    Miller, V. A.; Benedetti, F. M.; Rigas, J. R.; Verret, A. L.; Pfister, D. G.; Straus, D.; Kris, M. G.; Crisp, M.; Heyman, R.; Loewen, G. R.; more...
    Journal of Clinical Oncology (1997)

    Fulltext@MSK | Save